AngioDynamics Funds Jacobi Hospital Study to Improve Pulmonary Embolism Treatment Predictions
Event summary
- AngioDynamics awarded $50,000–$750,000 to Jacobi Hospital for a study on CT pulmonary angiography radiomics in pulmonary embolism (PE) treatment.
- The study will evaluate imaging biomarkers to predict thrombectomy success and long-term outcomes in PE patients.
- The ALPHA-PE Research Fund, a partnership between AngioDynamics and The PERT Consortium®, supports independent, physician-led research in PE care.
- The research aims to provide real-world evidence to support more informed treatment decisions for PE.
The big picture
AngioDynamics' funding of this study underscores the growing emphasis on real-world evidence in medical device innovation. The research addresses a critical gap in understanding clot composition and response to mechanical thrombectomy, potentially enabling more personalized treatment approaches. This aligns with broader industry trends toward value-based healthcare and data-driven decision-making in interventional cardiology.
What we're watching
- Evidence Generation
- How the study's findings will impact clinical decision-making and treatment protocols for PE.
- Market Differentiation
- Whether AngioDynamics can leverage this research to strengthen its position in the PE treatment market.
- Regulatory Impact
- The pace at which real-world evidence from this study could influence regulatory approvals or guidelines for PE treatments.